Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Growth hormone deficiency in children, after treatment for childhood cancer

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; SKION LATER Q2008 onderzoek: Growth hormone deficiency in children, after treatment for childhood cancer - SKION LATER Q2008 - growth hormone child

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41436

Enrollment

400

Registered

2015-01-23

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth hormone deficiency in childhood cancer survivors shortage of growth hormone after treatment for childhood cancer

Interventions

None listed

Eligibility

Age

12 Years to 17 Years

Inclusion criteria

Inclusion criteria: All patients who were treated for childhood cancer (before age 18) in one of the seven Pediatric Oncology Centers between 1960 and 2001 and who survived for at least 5 years after diagnosis will be included in the SKION LATER study. Participating centres are located in Amsterdam (the Emma Children's Hospital/ Academic Medical Centre (EKZ/AMC) and the VU University Medical Center (VUMC) and), Groningen (Children's Cancer Center/ University Medical Center Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen (University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology (PMC)). From this cohort of 575 survivors, 400 childhood cancer survivors will be asked to participate in the growth hormone study.

Exclusion criteria

Exclusion criteria: Diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >17 years or diagnosis while residing in foreign country , abnormal thyroid function tests, kidney or liver values. BMI

Design outcomes

Primary

Measure	Time frame
* Mean height (in non-disproportional patients) at near final height * Height distribution (in non-disproportional patients) at near final height * IGF-1 distribution compared with normal population/sibs * IGF-BP3 distribution compared with normal population/sibs * % of cancer survivors with an IGF-1	—

Countries

Netherlands

Outcome results